Delayed Release Prednisone in PMR

Status Terminated

Clinical Trial Summary

A four-week, randomized, controlled, open-label trial of DR prednisone in which patients receive in period 1 one of three-night time doses of treatment (4mg, 7mg or 10mg) for two weeks followed in period 2 by treatment with 15mg IR prednisone in the morning for two weeks. Period 1 is randomized and open-label and period 2 is open label. Before enrollment and randomization patient diagnosis and responsiveness to 15mg IR prednisone in the morning is established. 45 patients will be randomized, 15 patients in each treatment arm.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02702778
Study type	Interventional
Source	Dinora, Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	February 2016
Completion date	March 31, 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04972968` - A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154	Phase 2
Active, not recruiting	`NCT04519580` - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Terminated	`NCT03600818` - Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica	Phase 3
Completed	`NCT00836810` - Timed Release Tablet Prednisone in Polymyalgia Rheumatica	Phase 2/Phase 3
Completed	`NCT04239521` - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed	`NCT03263715` - A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)	Phase 3
Recruiting	`NCT05935709` - DANIsh VASculitis Database (DANIVAS)
Not yet recruiting	`NCT02985424` - Polymyalgia Rheumatica and Giant Cell Arteritis	N/A
Completed	`NCT00138983` - Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.	Phase 3
Recruiting	`NCT06130540` - Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR	Phase 1
Recruiting	`NCT05767034` - Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)	Phase 3
Terminated	`NCT01821040` - A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR	Phase 3
Recruiting	`NCT00982332` - Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica	N/A
Recruiting	`NCT05312944` - Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
Recruiting	`NCT04664465` - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Withdrawn	`NCT02899026` - Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica	Phase 3
Not yet recruiting	`NCT06281236` - A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)	Phase 1
Recruiting	`NCT03576794` - Treatment With Leflunomide in Patients With Polymyalgia Rheumatica	Phase 3
Completed	`NCT05681676` - Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
Recruiting	`NCT05435781` - Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency	Phase 4